NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)-- BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult stem cell technologies and therapeutics, today announced the election of Jonathan C. Javitt, M.D., M.P.H. to its Board of Directors. The addition of Dr. Javitt to Brainstorm’s team demonstrates the company’s significant strides in its research as it begins the crucial clinical phases of its research; at the same time the company is ramping up for its FDA approval process as indicated through the addition of key advisors with substantial FDA experiences.
